EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS

Wisse R Bakker iD, Linda Remijn-Nelissen, Teun van Gelder, Romina Shahini iD, Jan J G M Verschuuren, Martijn R Tannemaat iD

Journal of Neuromuscular Diseases · 17.08.2026

DOI: 10.1177/22143602261477475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 17.08.2026. Verfasst von Wisse R Bakker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy & Toxicology, Leiden University Medical Centre, Leiden, The Netherlands. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Argenx.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular junction disorder characterized by muscle weakness and autonomic dysfunction. While amifampridine is the established first-line symptomatic treatment, longitudinal data regarding the evolution of therapeutic regimens over time and the use of immunosuppressive therapies remain limited. This retrospective study analyzed 70 LEMS patients treated at the Leiden University Medical Center (LUMC) between 1992 and 2023. Treatment was evaluated and a four-point “leg score” was developed and used to retrospectively quantify functional impairment and response to amifampridine. Sixty-six percent of the cohort was female, the median age of diagnosis was 54 years and non-tumor LEMS was more prevalent (77%). All patients used amifampridine at some point, and 91% initiated it within six months of diagnosis. Amifampridine improved leg scores in 57% of patients. Although 58% of patients reported side effects (mostly paresthesia), discontinuation was rare (7%). Pyridostigmine was used in 81% of patients. Immunosuppressive drug use—predominantly prednisolone and azathioprine —increased over time, reaching 44% after five years. Conversely, azathioprine, prednisolone and pyridostigmine were discontinued by 50%, 38% and 32% of patients, respectively, often due to adverse effects. In conclusion, amifampridine provides significant clinical benefits and remains the cornerstone of LEMS therapy. Immunomodulatory therapies were introduced gradually and their use increased over time. Compared with autoimmune myasthenia gravis, immunomodulatory therapy was used less frequently during the early disease course of LEMS.

Schlagwörter

Stichwörter der Autor:innen

amifampridineimmunosuppressive treatmentlamber-eaton myasthenic syndromelongitudinal treatment patternsneuromuscular disease

Autor:innen und Institutionen

  • Department of Clinical Pharmacy & Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.

ORCID-Profile: Wisse R Bakker, Romina Shahini, Martijn R Tannemaat

Förderung

  • Argenx

Zitieren

APA

Bakker, W. R., Remijn-Nelissen, L., van Gelder, T., Shahini, R., Verschuuren, J. J. G. M., & Tannemaat, M. R. (2026). Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS. Journal of Neuromuscular Diseases. https://doi.org/10.1177/22143602261477475

Vancouver

Bakker WR, Remijn-Nelissen L, van Gelder T, Shahini R, Verschuuren JJGM, Tannemaat MR. Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS. Journal of Neuromuscular Diseases. 2026. doi:10.1177/22143602261477475

BibTeX
@article{Bakker2026,
  author = {Bakker, Wisse R and Remijn-Nelissen, Linda and van Gelder, Teun and Shahini, Romina and Verschuuren, Jan J G M and Tannemaat, Martijn R},
  title = {Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS},
  journal = {Journal of Neuromuscular Diseases},
  year = {2026},
  doi = {10.1177/22143602261477475}
}
Kostenlos starten →